<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lentigo maligna: Clinical manifestations, diagnosis, and management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lentigo maligna: Clinical manifestations, diagnosis, and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Lentigo maligna: Clinical manifestations, diagnosis, and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arthur J Sober, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Suzanne Olbricht, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Angela M Hong, MBBS, MMed, PhD, FRANZCR</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hensin Tsao, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 10, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H244299021"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Lentigo maligna (LM) is a type of melanoma in situ that typically occurs in sun-damaged skin of the face and neck of older individuals  (<a class="graphic graphic_picture graphicRef62052 graphicRef59591 graphicRef68787 graphicRef75238 graphicRef77206" href="/d/graphic/62052.html" rel="external">picture 1A-E</a>) [<a href="#rid1">1</a>]. LM evolves slowly over many years and may progress to invasive lentigo maligna melanoma (LMM). "Hutchinson melanotic freckle" and "melanosis circumscripta precancerosa of Dubreuilh" are synonyms of LM [<a href="#rid2">2,3</a>].</p><p>This topic will discuss the clinical features, diagnosis, and treatment of LM. LMM is discussed separately. (See  <a class="medical medical_review" href="/d/html/15806.html" rel="external">"Melanoma: Clinical features and diagnosis", section on 'Lentigo maligna melanoma'</a> and  <a class="medical medical_review" href="/d/html/4843.html" rel="external">"Pathologic characteristics of melanoma", section on 'Lentigo maligna melanoma'</a>.)</p><p class="headingAnchor" id="H244299028"><span class="h1">EPIDEMIOLOGY AND NATURAL HISTORY</span><span class="headingEndMark"> — </span>Lentigo maligna (LM) usually occurs in older individuals, with a peak incidence between 65 and 80 years [<a href="#rid4">4,5</a>]. The incidence of LM appears to be increasing in younger age groups. One study reported a 52 percent increase in the incidence rate of LM among males and females aged 45 to 64 years between 1990 and 2000 in the United States [<a href="#rid6">6</a>]. An analysis of Surveillance, Epidemiology, and End Results (SEER) data reported an increase of LM incidence between 2000 and 2019 from 4.16 to 5.61 per 100,000 person years [<a href="#rid7">7</a>]. The risk of LM and lentigo maligna melanoma (LMM) is higher in individuals with lightly pigmented skin, markers of actinic skin damage (solar lentigines and actinic keratoses), and a history of nonmelanoma skin cancer [<a href="#rid8">8,9</a>].</p><p>LM is a slowly evolving lesion and is often diagnosed years or decades after its initial onset. In some lesions, partial central regression may occur while the peripheral margin continues to extend [<a href="#rid10">10,11</a>]. The time to progression of LM to invasive LMM ranges from less than 10 to more than 50 years [<a href="#rid10">10,12</a>].</p><p>The lifetime risk of progression of LM to LMM was estimated to be approximately 5 percent [<a href="#rid13">13</a>]. However, these data are old, and, in some series, up to 20 percent of patients undergoing excision for LM were found to have invasive disease [<a href="#rid14">14-17</a>].</p><p class="headingAnchor" id="H244299035"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Lentigo maligna (LM) usually presents as an atypical, pigmented, macular lesion localized on severely sun-damaged skin of the head or neck. Clinical features of LM include  (<a class="graphic graphic_picture graphicRef62052 graphicRef59591 graphicRef68787 graphicRef75238 graphicRef77206" href="/d/graphic/62052.html" rel="external">picture 1A-E</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Irregular shape</p><p class="bulletIndent1"><span class="glyph">●</span>Variable color, from light brown or tan to dark brown, black, pink, red, or white</p><p class="bulletIndent1"><span class="glyph">●</span>Variable size, from less than one to several centimeters</p><p class="bulletIndent1"><span class="glyph">●</span>Nonscaly, smooth surface</p><p></p><p>Pink or white areas indicate inflammation or regression. The nose, cheeks, and ears are preferentially involved. Infrequently, LM occurs in nonhead and neck locations, such as the upper back, forearms, dorsum of the hands, and legs [<a href="#rid18">18,19</a>]. The surrounding skin typically shows evidence of chronic solar damage (solar elastosis, solar lentigines, or actinic keratoses). The borders may be ill defined. Amelanotic LM is rare [<a href="#rid20">20</a>].</p><p>The development of darker pigmentation, sharper borders, or elevated or nodular areas are clinical signs of progression to lentigo maligna melanoma (LMM)  (<a class="graphic graphic_picture graphicRef62105 graphicRef57765 graphicRef74664 graphicRef54753" href="/d/graphic/62105.html" rel="external">picture 2A-D</a>). Rarely, a desmoplastic melanoma may develop within an LM, presenting as a plaque, nodule, or palpable subcutaneous firmness that may have a scar-like feel [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/4843.html" rel="external">"Pathologic characteristics of melanoma", section on 'Desmoplastic melanoma'</a>.)</p><p class="headingAnchor" id="H2436682"><span class="h1">DERMOSCOPIC FEATURES</span><span class="headingEndMark"> — </span>In nonfacial and nonvolar skin lesions, the presence of a pigment network, which correlates with the rete ridge pattern of the skin, is commonly associated with melanocytic neoplasms. The quality and distribution of this network can help in differentiating nevi from melanoma [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/13521.html" rel="external">"Overview of dermoscopy"</a> and  <a class="medical medical_review" href="/d/html/13522.html" rel="external">"Dermoscopic evaluation of skin lesions"</a>.)</p><p>Because of the unique features of facial skin (absence or flattening of rete ridges and increased number and prominence of hair follicles and sweat gland ostia), pigmented lesions occurring on the face do not show a pigment network when examined with a dermatoscope. In contrast, the distribution of the pigmentation around the prominent hair follicles forms a pseudonetwork that is seen in both melanocytic and nonmelanocytic lesions (eg, seborrheic keratoses) [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/d/html/93602.html" rel="external">"Dermoscopy of facial lesions"</a>.)</p><p>Since the pseudonetwork does not discriminate melanocytic from nonmelanocytic lesions, other dermoscopic criteria are used for the diagnosis of facial lesions. Horn pseudocysts, yellow opaque areas, fingerprint-like structures, moth-eaten pattern, and jelly sign suggest solar lentigo or flat seborrheic keratosis, whereas the features most frequently seen in lentigo maligna (LM) and lentigo maligna melanoma (LMM) include  (<a class="graphic graphic_picture graphicRef96316 graphicRef96318 graphicRef96313 graphicRef96319 graphicRef96312 graphicRef96314" href="/d/graphic/96316.html" rel="external">picture 3A-F</a>) [<a href="#rid24">24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Asymmetric, pigmented follicular openings (atypical pseudonetwork)  (<a class="graphic graphic_picture graphicRef96312" href="/d/graphic/96312.html" rel="external">picture 3E</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Angulated lines (usually gray in color) that can coalesce to form polygons, with the most common form being rhomboidal structures  (<a class="graphic graphic_picture graphicRef96317" href="/d/graphic/96317.html" rel="external">picture 4</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Annular-granular pattern consisting of asymmetric, pigmented follicular openings and/or gray dots/granules/globules surrounding ostial openings  (<a class="graphic graphic_picture graphicRef96316" href="/d/graphic/96316.html" rel="external">picture 3A</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Occasionally, circle within a circle can also be seen in LM  (<a class="graphic graphic_picture graphicRef96313" href="/d/graphic/96313.html" rel="external">picture 3C</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gray pseudonetwork.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gray areas.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gray dots and globules.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dark blotches in-between ostial openings or completely obliterating the ostial openings.</p><p></p><p>Many of the features seen in LM can also be seen in pigmented actinic keratosis, which is believed to be a collision between a solar lentigo and an actinic keratosis [<a href="#rid25">25</a>]. While subtle dermoscopic features can assist in differentiating an actinic keratosis from LM, palpation of the lesion can also help. Pigmented actinic keratosis will have a rough texture while LM typically has a smooth texture. (See  <a class="medical medical_review" href="/d/html/93602.html" rel="external">"Dermoscopy of facial lesions", section on 'Lentigo maligna and lentigo maligna melanoma'</a>.)</p><p>One study found that four dermoscopic features have high sensitivity and specificity (89 and 96 percent, respectively) for the diagnosis of LM or LMM  (<a class="graphic graphic_picture graphicRef68828 graphicRef63812" href="/d/graphic/68828.html" rel="external">picture 5A-B</a>) [<a href="#rid26">26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Asymmetrical, pigmented follicular openings (atypical pseudonetwork)</p><p class="bulletIndent1"><span class="glyph">●</span>Rhomboidal structures</p><p class="bulletIndent1"><span class="glyph">●</span>Gray globules</p><p class="bulletIndent1"><span class="glyph">●</span>Gray dots</p><p></p><p>Another study found that, irrespective of the specific dermoscopic pattern seen in a lesion, the presence of gray color, seen in approximately 90 percent of cases, was the single most important criterion in the diagnosis of LM [<a href="#rid27">27</a>]. However, despite having a high sensitivity, gray color lacks specificity, since it can also be seen in lichen planus-like keratosis  (<a class="graphic graphic_picture graphicRef96329" href="/d/graphic/96329.html" rel="external">picture 6</a>) and pigmented actinic keratosis  (<a class="graphic graphic_picture graphicRef96297" href="/d/graphic/96297.html" rel="external">picture 7</a>). (See  <a class="medical medical_review" href="/d/html/93602.html" rel="external">"Dermoscopy of facial lesions", section on 'Lichen planus-like keratosis'</a>.)</p><p>Although dermoscopy is helpful in the clinical diagnosis of benign facial lesions, such as solar lentigines and seborrheic keratoses, biopsy and histopathology evaluation remain the gold standard for the diagnosis of LM or pigmented actinic keratosis. Lesions showing dermoscopic features suspicious of LM should be biopsied for histopathologic confirmation. For large LM lesions requiring incisional biopsy for the initial diagnosis, dermoscopy may be useful in targeting areas with the most atypical findings for biopsy. Alternatively, multiple punch biopsies (scouting biopsies) can also be used. (See <a class="local">'Biopsy and histologic examination'</a> below.)</p><p class="headingAnchor" id="H244299042"><span class="h1">HISTOPATHOLOGIC FEATURES</span><span class="headingEndMark"> — </span>Histologically, lentigo maligna (LM) is a melanoma in situ characterized by an increased number of atypical melanocytes, often spindle shaped, arranged in single cells or in small nests along the dermoepidermal junction, often extending into the infundibular portion of hair follicles  (<a class="graphic graphic_picture graphicRef60447 graphicRef53790" href="/d/graphic/60447.html" rel="external">picture 8A-B</a>) [<a href="#rid28">28</a>]. Melanocytic atypia ranges from near normal to multinucleated melanocytes or melanocytes with dendritic processes [<a href="#rid29">29</a>]. Cytoplasm retraction artifacts may be seen. (See  <a class="medical medical_review" href="/d/html/4843.html" rel="external">"Pathologic characteristics of melanoma", section on 'Melanoma in situ'</a>.)</p><p>Of note, LM may be quite subtle histologically and is often difficult to distinguish from actinic melanocytic hyperplasia. The presence of melanocytic nesting, confluence of &gt;3 melanocytes along the dermoepidermal junction, and pagetoid spread are helpful diagnostic clues.</p><p>Changes of chronic solar damage usually coexist, including elastosis, atrophy of the epidermis, effacement of rete ridges, and inflammatory dermal infiltrate [<a href="#rid12">12</a>]. Determining the histologically clear margin of LM is particularly difficult because the transition between LM and melanocytic hyperplasia of sun-damaged skin is often subtle. A biopsy specimen of normal-appearing but sun-damaged skin, taken as a control, may aid in this distinction since it provides a reference for the background level of melanocytic hyperplasia in a given individual [<a href="#rid30">30</a>].</p><p>Immunostaining with a nuclear antibody, such as Sox10 or microphthalmia transcription factor (MITF), is recommended to accurately assess cellularity and nuclear morphology; stains that target cytoplasmic antigens, such as HMB-45 and Melan-A, may overestimate the cellularity of the lesion [<a href="#rid31">31,32</a>].</p><p class="headingAnchor" id="H20157199"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H1146732"><span class="h2">Clinical and dermoscopic examination</span><span class="headingEndMark"> — </span>The diagnosis of lentigo maligna (LM) is based upon clinical, dermoscopic, and histologic examination [<a href="#rid33">33</a>]. (See <a class="local">'Clinical features'</a> above and <a class="local">'Dermoscopic features'</a> above and <a class="local">'Histopathologic features'</a> above.)</p><p>The clinical diagnosis of LM at an early stage may be difficult even for the experienced dermatologist. On clinical examination, the recognition of LM is often complicated by the presence of multiple lesions that are similar in appearance, including solar lentigines, flat seborrheic keratoses, and pigmented actinic keratoses.</p><p>Dermoscopy may be helpful in differentiating early LM from benign, pigmented lesions occurring on sun-damaged skin, such as seborrheic keratoses and solar lentigines. However, differentiating a pigmented actinic keratosis from LM by dermoscopy is difficult and not always possible. Pigmented actinic keratoses are a rare variant of actinic keratosis that share clinical and dermoscopic features with LM. (See <a class="local">'Dermoscopic features'</a> above and <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H3884497206"><span class="h2">Reflectance confocal microscopy</span><span class="headingEndMark"> — </span>Reflectance confocal microscopy (RCM), also called confocal scanning laser microscopy, is a noninvasive, complex technique for the imaging of human skin, with cellular resolution from the stratum corneum to approximately the level of the papillary dermis. RCM has been evaluated in a small number of patients for the differentiation of LM from other pigmented lesions of the face [<a href="#rid34">34-37</a>]. In one study comparing the diagnostic accuracy of RCM and dermoscopy in the evaluation of 223 facial lesions, RCM was more sensitive than dermoscopy for the diagnosis of LM and lentigo maligna melanoma (LMM; 80 versus 61 percent) but less specific (81 versus 92 percent) [<a href="#rid38">38</a>]. Moreover, RCM showed a higher sensitivity than dermoscopy for the diagnosis of hypomelanotic and recurrent LM/LMM (69 versus 37 percent).</p><p>In preliminary studies, RCM has also been used for preoperative margin mapping of LMs with promising results [<a href="#rid39">39,40</a>]. However, RCM is available only at specialized dermatologic institutions, requires specialized training, and data on its diagnostic accuracy are limited [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H244299049"><span class="h2">Biopsy and histologic examination</span><span class="headingEndMark"> — </span>Biopsy is necessary to establish the diagnosis of LM. Excisional biopsy with narrow margins is ideal, although a saucerization (deep shave) may be adequate in some cases. Since abnormal melanocytic cells may extend down the adventitia of the hair follicles, a more superficial shave is not adequate for accurate diagnosis, since it may not include this area for evaluation and, therefore, lack information as to whether there is deep follicular extension or invasion. According to the National Comprehensive Cancer Network (NCCN) guidelines, a broad shave biopsy may help to optimize accurate diagnosis [<a href="#rid42">42</a>].</p><p>For LMs that are broad and located on cosmetically sensitive sites, partial biopsy (punch or incisional biopsy) may be performed. However, considerable sampling errors can occur with partial biopsies because the histopathologic findings may vary within the lesion. Evidence of dermal invasion has been reported in up to 20 percent of specimens with a preoperative diagnosis of LM on initial biopsy [<a href="#rid14">14-17</a>]. Multiple scouting biopsies may be needed for large lesions.</p><p>The choice of the site(s) for incisional biopsy is based upon clinical examination, dermoscopy, and, where available, RCM [<a href="#rid43">43</a>]. The most irregular or heavily pigmented areas identified by clinical and/or dermoscopic examination and any palpable or thickened areas are the preferred biopsy sites. It is good practice to indicate on the pathology requisition that a partial biopsy of a larger lesion was performed. (See <a class="local">'Dermoscopic features'</a> above.)</p><p>Histologically, the replacement of basal keratinocytes by atypical melanocytes with background changes of chronic sun damage (epidermal atrophy, effacement of rete ridges, and inflammatory dermal infiltrate) is diagnostic of LM. Microscopic features of benign solar lentigo, actinic keratosis, LM, and LMM may coexist in the same lesion. (See <a class="local">'Histopathologic features'</a> above.)</p><p class="headingAnchor" id="H20157231"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Lentigo maligna (LM) should be differentiated from other melanocytic and nonmelanocytic lesions, including:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Solar lentigo</strong> – Solar lentigines are macular lesions with irregular margins and uniform, brown pigmentation. Solar lentigines are commonly seen on chronically sun-exposed sites (face, dorsum of hands) of older individuals with fair skin and a history of excessive sun exposure  (<a class="graphic graphic_picture graphicRef81287 graphicRef61452" href="/d/graphic/81287.html" rel="external">picture 9A-B</a>). In contrast with solar lentigines, the macular lesions of LM tend to be darker and irregularly pigmented. On dermoscopy, solar lentigines show faint, pigmented, fingerprint structures  (<a class="graphic graphic_picture graphicRef96289" href="/d/graphic/96289.html" rel="external">picture 10</a>) or a structureless pattern, whereas LM exhibit a range of dermoscopic features related to follicular and interfollicular structures  (<a class="graphic graphic_picture graphicRef96316 graphicRef96318 graphicRef96313 graphicRef96319 graphicRef96312 graphicRef96314" href="/d/graphic/96316.html" rel="external">picture 3A-F</a>) and shades of gray color. Histologically, solar lentigo is characterized by acanthosis with regular elongation of the rete ridges and hyperpigmentation, and either no or mild increase in basally located, cytologically benign melanocytes without nesting or confluence. (See  <a class="medical medical_review" href="/d/html/5560.html" rel="external">"Benign pigmented skin lesions other than melanocytic nevi (moles)", section on 'Solar lentigo'</a> and  <a class="medical medical_review" href="/d/html/93602.html" rel="external">"Dermoscopy of facial lesions", section on 'Solar lentigo'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pigmented actinic keratosis</strong> – Pigmented actinic keratoses present as scaly, hyperpigmented macules or patches occurring on sun-exposed skin of adult individuals with fair complexion. Pigmented actinic keratoses are difficult to differentiate from LM by the naked eye or dermoscopic examination  (<a class="graphic graphic_picture graphicRef96223" href="/d/graphic/96223.html" rel="external">picture 11</a>). Histologically, there is a proliferation of atypical keratinocytes extending from the basal layer upward, with increased melanin in the lower epidermis and dermal melanophages. (See  <a class="medical medical_review" href="/d/html/13712.html" rel="external">"Actinic keratosis: Epidemiology, clinical features, and diagnosis", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/d/html/13712.html" rel="external">"Actinic keratosis: Epidemiology, clinical features, and diagnosis", section on 'Pathology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Seborrheic keratosis</strong> – Seborrheic keratoses are common, benign, keratinocytic tumors presenting as macular or elevated lesions, with variable brown pigmentation and a verrucous surface  (<a class="graphic graphic_picture graphicRef58445" href="/d/graphic/58445.html" rel="external">picture 12</a>). Dermoscopic examination is helpful in differentiating seborrheic keratosis from LM. Characteristic dermoscopic patterns seen in seborrheic keratoses include moth-eaten borders  (<a class="graphic graphic_picture graphicRef96676" href="/d/graphic/96676.html" rel="external">picture 13</a>), milia-like cysts  (<a class="graphic graphic_picture graphicRef96677" href="/d/graphic/96677.html" rel="external">picture 14</a>), comedo-like openings  (<a class="graphic graphic_picture graphicRef96678" href="/d/graphic/96678.html" rel="external">picture 15</a>), and fissures and ridges  (<a class="graphic graphic_picture graphicRef96682" href="/d/graphic/96682.html" rel="external">picture 16</a>). Histologically, seborrheic keratoses show a proliferation of normal keratinocytes, and some variants (eg, melanoacanthoma) can show an increased number of melanocytes. (See  <a class="medical medical_review" href="/d/html/5573.html" rel="external">"Overview of benign lesions of the skin", section on 'Seborrheic keratosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lentigo maligna melanoma </strong>– Lentigo maligna melanoma (LMM) results from the progression of LM to the invasive phase. Clinically, it presents as a hyperpigmented patch, with darker, asymmetric foci or nodules  (<a class="graphic graphic_picture graphicRef74664 graphicRef54753" href="/d/graphic/74664.html" rel="external">picture 2C-D</a>). On dermoscopy, the presence of pigmented, rhomboidal structures  (<a class="graphic graphic_picture graphicRef96317" href="/d/graphic/96317.html" rel="external">picture 4</a>) and structureless, gray-black blotches corresponding to obliterate hair follicles  (<a class="graphic graphic_picture graphicRef96315" href="/d/graphic/96315.html" rel="external">picture 17</a>) are clues to the diagnosis of LMM. Histologically, neoplastic melanocytes are arrayed along the dermal-epidermal junction in a lentiginous pattern and form nests along the dermal-epidermal junction and nodules or fascicles in the dermis  (<a class="graphic graphic_picture graphicRef73737" href="/d/graphic/73737.html" rel="external">picture 18</a>). (See  <a class="medical medical_review" href="/d/html/4843.html" rel="external">"Pathologic characteristics of melanoma", section on 'Lentigo maligna melanoma'</a>.)</p><p></p><p class="headingAnchor" id="H244299056"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H651881"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Although there is some variation in the treatment approach for lentigo maligna (LM) among clinicians, surgical excision is the preferred option for most lesions [<a href="#rid44">44,45</a>]. However, the optimal excision margins for LM have not been evaluated in randomized trials [<a href="#rid46">46</a>]. National and international guidelines recommend standard excision with 5 to 10 mm margins as first-line therapy for all types of melanoma in situ, including LM [<a href="#rid42">42,47-53</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>The 2018 Australian melanoma guidelines state that melanoma in situ should be excised with 5 to 10 mm margins, with the aim of achieving complete histologic clearance and that minimum clearances from all margins should be assessed and stated [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>2018 guidelines from the American Academy of Dermatology, as well as the National Comprehensive Cancer Network (NCCN) guidelines, state that LM may require excision margins of 5 to 10 mm to achieve histologically negative margins [<a href="#rid54">54,55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A minimum excision margin of 5 mm is also recommended by the 2016 European consensus-based interdisciplinary guidelines [<a href="#rid51">51</a>].</p><p></p><p>Additional surgical techniques that are frequently used in clinical practice include staged excisions and Mohs micrographic surgery (MMS). These allow a complete margin assessment while sparing normal tissue. (See <a class="local">'Staged excision'</a> below and <a class="local">'Mohs micrographic surgery'</a> below.)</p><p>Alternative nonsurgical treatments for LM include radiation therapy (RT) and topical immunomodulator therapy with <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a>. Nonsurgical therapies may be appropriate in older, frail patients with large lesions of the face that cannot be resected with adequate margins, when problematic reconstruction is anticipated, and in those who decline surgery. None of these treatment modalities has been compared with surgery in randomized trials. (See <a class="local">'Nonsurgical therapies'</a> below.)</p><p class="headingAnchor" id="H3608057150"><span class="h2">Surgery</span><span class="headingEndMark"> — </span>For most patients with LM, we suggest surgical excision rather than nonsurgical therapies as first-line treatment. Surgical techniques that can be used for LM include wide local excision with margins of at least 5 to 10 mm and staged excision with rush permanent sections ("slow Mohs"), which allows a complete histopathologic evaluation of surgical margins. Mohs surgery may also be an option for LM. However, margin assessment of LM with frozen sections can be problematic [<a href="#rid56">56</a>]. The choice of the surgical technique is based on the size and location of the lesion, consideration of cosmetic and functional outcomes, and clinical experience.</p><p class="headingAnchor" id="H2219159414"><span class="h3">Delineating the lesion margins</span><span class="headingEndMark"> — </span>Prior to surgical excision, it is important to assess the extent of LM and delineate the lesion margins as accurately as possible. Methods used for preliminary mapping of the margins include examination under a Wood's lamp, performing multiple scouting biopsies, and, where available, using confocal microscopy [<a href="#rid39">39,57,58</a>]. (See <a class="local">'Reflectance confocal microscopy'</a> above.)</p><p class="headingAnchor" id="H1119024810"><span class="h3">Wide local excision</span><span class="headingEndMark"> — </span>We typically perform standard excision deep to the subcutaneous fat for small LM lesions (&lt;1 cm) with well-demarcated borders located on the forehead or cheeks, with margins of at least 5 mm and up to 10 mm if feasible, depending on the specific lesion location and consideration of function preservation and disfigurement. For lesions of any size on neck or upper chest, we perform standard excision with 10 mm margins.</p><p>The optimal excision margins for LM have not been evaluated in randomized trials [<a href="#rid46">46</a>]. Multiple studies using surgical techniques that allow a complete margin examination (eg, staged excision or Mohs surgery) indicate that margins of 5 or 6 mm provide clearance rates ranging from 24 to 84 percent, whereas margins of 7 to 15 mm may be required to achieve clearance rates of 94 to 99 percent [<a href="#rid16">16,59-64</a>]. A prospective study of 1506 LM cases and 829 melanomas in situ treated by Mohs surgery found that both LM and melanoma in situ located on the head and neck required a 12 mm margin to obtain complete clearance in 97 percent of the tumors, whereas a 9 mm margin was sufficient to clear lesions on the trunk and extremities [<a href="#rid64">64</a>]. Only 79 percent of LM and 83 percent of melanoma in situ were completely excised with a 6 mm margin.</p><p>A few retrospective studies have reported recurrence rates for standard excision of 6 to 9 percent after a mean follow-up time of 5 to 10 years [<a href="#rid65">65-68</a>].</p><p class="headingAnchor" id="H190891"><span class="h3">Staged excision</span><span class="headingEndMark"> — </span>We prefer staged excision with rush permanent sections ("slow Mohs") to wide local excision for large LM (&gt;1 cm) or clinically ill-defined lesions located on forehead and cheeks and lesions of any size located on the H area (also called "mask area") of the face, which includes central face, eyelids, eyebrows, periorbital, nose, lips, chin, mandible, preauricular, postauricular, temple, and ear  (<a class="graphic graphic_figure graphicRef103749" href="/d/graphic/103749.html" rel="external">figure 1</a>). Large (&gt;2 cm) lesions on the trunk or extremities with ill-defined margins, occurring in areas of marked sun damage with mottled pigmentation, may also benefit from staged excision. While reconstruction can often be done by the dermatologist in an outpatient setting, some wounds or patients may require reconstructive surgery performed under general anesthesia in the operating room.</p><p>Staged excision is considered by some experts to be the optimal surgical technique for LM, as it permits the evaluation of the surgical margins in a comprehensive manner similar to Mohs surgery but relies on permanent sections rather than frozen sections. Permanent sections require a longer processing time than frozen sections; however, rush readings can usually be obtained in less than 24 hours.</p><p>After delineating the LM clinical margins, a surgical margin of 5 mm is drawn around the lesion  (<a class="graphic graphic_figure graphicRef71333" href="/d/graphic/71333.html" rel="external">figure 2</a>). The gross clinical lesion ("tumor debulk") is excised down to the deep dermis, oriented, and sent to the laboratory as a fresh specimen or placed in a formalin bottle. The margins are then excised to the deep dermis, divided, marked to preserve orientation, and placed in individually labeled formalin bottles. The tumor debulk tissue is serially sectioned in various ways (multiple vertical "bread loaf" sections or radial sections) and examined for invasive melanoma [<a href="#rid69">69-73</a>]. The peripheral margins are inked with the same color consistently applied to the outer surface (true outer surgical margin). Each segment of the peripheral margin is sectioned vertically "en face" to allow the examination of the entire true margin. The permanent sections are evaluated by a dermatopathologist experienced in pigmented lesions. Some consulting pathologists prefer to receive an inked intact specimen, which they evaluate by the radial technique. It is important to have excellent communication between the surgeon and the pathologist on these cases. After the pathologist has examined the specimen histologically, the margin status and location of residual melanoma in situ is then communicated to the surgeon. The patient returns 24 to 48 hours later for reexcision of involved margins, and the process is repeated until negative peripheral margins are achieved. Reconstruction of the defect is then performed.</p><p>The wound is managed during the intervening time period by standard dressings. Electrocautery is performed to stop bleeding, and then the wound is cleaned with sterile <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> or soap and water. Petrolatum is applied to the wound, then it is covered with nonadherent dressing and secured by tape. We usually surmount this simple dressing with a pressure bandage constructed with rolled gauze, secured by tape. Large wounds do well with application of a sterile gauze impregnated with bismuth and petrolatum. The patient does not need to change the bandage since they will be returning for either further excision or repair of the defect. Deferring reconstruction is not harmful to the end result and has in fact been shown to be associated with fewer postoperative complications when repair is done with a full-thickness skin graft [<a href="#rid74">74</a>].</p><p>There are several variations of the staged excision, including the "square procedure," perimeter, contoured, spaghetti, and serial disk techniques [<a href="#rid75">75-80</a>]. In some of these techniques, the margin specimens are cut en face in vertical sections that contain 100 percent of the peripheral margins. These techniques generally deal with the margins first, leaving the center part of the lesion in situ until the margins are clear. While the patient may be somewhat more comfortable in the intervening period without a large wound, there is a 10 to 20 percent risk of identifying invasive lentigo maligna melanoma (LMM) requiring deeper excision only at the end of the process [<a href="#rid14">14-17</a>].</p><p>Recurrence rates of 0 to 6 percent have been reported after staged excision at a mean follow-up time of 23 to 138 months [<a href="#rid15">15,68-72,78,80-82</a>].</p><p class="headingAnchor" id="H190898"><span class="h3">Mohs micrographic surgery</span><span class="headingEndMark"> — </span>Mohs micrographic surgery (MMS) is a technique that involves a beveled excision of the tumor with a margin of normal-appearing tissue using a scalpel angled at 45 degrees to the skin surface. MMS uses frozen horizontal sections that allow for examination of the entire peripheral and deep margins of the tumor with maximal preservation of uninvolved tissue and is especially useful for the treatment of nonmelanoma skin cancers in cosmetically sensitive areas. (See  <a class="medical medical_review" href="/d/html/13708.html" rel="external">"Mohs surgery"</a>.)</p><p>We do not perform Mohs surgery with frozen section for the treatment of LM. Differentiating atypical melanocytic hyperplasia from benign melanocytic hyperplasia or actinic keratinocytic damage is difficult on frozen section and requires considerable experience in MMS and high-quality frozen sections [<a href="#rid83">83</a>]. Rapid immunostaining with MART-1 or Mel-5 may help in identifying the melanocytes on frozen sections and appears to provide information similar to that obtained from permanent sections [<a href="#rid84">84-86</a>]. Some Mohs surgeons, after a final negative frozen layer, excise an additional margin of 1 to 3 mm and send it for permanent sections. Some also send the central debulking specimen for permanent vertical sections for a more accurate staging of the tumor.</p><p>In one study including 116 patients with LM, 5 percent of margins that were negative on frozen sections were positive on permanent sections [<a href="#rid87">87</a>]. In a review of 173 cases with an initial diagnosis of LM or melanoma in situ and treated with MMS, the examination of permanent sections of the central debulking specimens led to an upstaging of the tumor in 14 (8 percent) of cases [<a href="#rid88">88</a>]. In another review of LM and LMM cases treated with a staged excision technique with rush paraffin-embedded sections, 15 of 91 cases (16 percent) that were initially diagnosed as LM were found to be invasive melanomas [<a href="#rid16">16</a>].</p><p>Recurrence rates of 0 to 2 percent have been reported for LM excised by MMS after a follow-up time of 29 to 44 months [<a href="#rid65">65,84,89-92</a>].</p><p class="headingAnchor" id="H652399"><span class="h2">Nonsurgical therapies</span></p><p class="headingAnchor" id="H2526195546"><span class="h3">Overview</span><span class="headingEndMark"> — </span>Nonsurgical therapy for LM should only be considered under selected clinical circumstances: in older, frail patients in whom surgical excision is not feasible; when problematic reconstruction is anticipated; and in patients who decline surgery [<a href="#rid55">55</a>]. Alternatives to surgery include radiotherapy, topical <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a>, cryosurgery, and laser therapy.</p><p>Nonsurgical techniques have not been evaluated in randomized trials.</p><p class="bulletIndent1"><span class="glyph">●</span>One study reviewed 1086 cases of melanoma in situ treated with surgery or nonsurgical interventions. Overall, 721 cases involved the head or neck. The five-year recurrence rate was 6.8 percent for surgical excision and 31 percent for radiotherapy, laser therapy, and cryosurgery combined as a single category [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An international, randomized <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT02394132&amp;token=nbsXe3i4qfUea5RCPRHtOY5G%2FPzFIESeuM6wIJ4nJiSqvxXnNQehQaqfkrCMQyBCrIB55MEb9t6pAOSAn3EfxA%3D%3D&amp;TOPIC_ID=13520" target="_blank">trial</a> comparing RT with <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a> is being conducted by the Melanoma and Skin Cancer Trials group in patients with LM in whom surgery is not suitable. The primary endpoint of the trial is the proportion of patients experiencing LM recurrence (as determined by dermoscopy and/or reflectance confocal microscopy [RCM] and confirmed by biopsy) at 24 months following completion of treatment.</p><p></p><p>Drawbacks of nonsurgical therapies include:</p><p class="bulletIndent1"><span class="glyph">●</span>Lack of histologic examination of the entire tumor for foci of dermal invasion not evident at the initial biopsy. In a series of 117 LM and LMM treated with staged excision, unsuspected invasive melanoma was found in 16 percent of specimens initially diagnosed as LM [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lack of histologic margin control.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Post-treatment monitoring based upon clinical examination or random biopsies that may not show tumor persistence or recurrence. </p><p></p><p class="headingAnchor" id="H244299072"><span class="h3">Radiation therapy</span><span class="headingEndMark"> — </span>Radiation therapy (RT) is not commonly used as a primary therapy for LM. However, RT may be a treatment option for older patients who have large LM lesions and for whom surgical removal would not be feasible or desirable due to the impact on functional and cosmetic outcome  (<a class="graphic graphic_picture graphicRef120598" href="/d/graphic/120598.html" rel="external">picture 19</a>). RT can also be used as adjuvant treatment in patients with positive margins following surgical excision when further surgical resection is not feasible [<a href="#rid42">42,94</a>]. The gross tumor volume is the lesion delineated by methods listed above (see <a class="local">'Delineating the lesion margins'</a> above), and the clinical target volume is 5 to 10 mm in addition to the gross tumor volume. An appropriate radiation energy and technique are dependent on the size, contour, and location of the lesion. </p><p>The NCCN guidelines suggest the following potential regimens [<a href="#rid42">42</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>64 to 70 Gy in 32 to 35 fractions over six to seven weeks</p><p class="bulletIndent1"><span class="glyph">●</span>50 to 57 Gy in 20 to 23 fractions in four to five weeks</p><p class="bulletIndent1"><span class="glyph">●</span>35 Gy in five fractions over one week for fields &lt;3 cm<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>32 Gy in four fractions per week</p><p></p><p>A typical dose is 50 to 56 Gy in 2 Gy fractions with superficial energy radiation treating to a depth of 5 mm. (See  <a class="medical medical_review" href="/d/html/7614.html" rel="external">"Radiation therapy in the management of melanoma", section on 'Cutaneous primary lesions'</a>.)</p><p>In Europe, low energy Grenz rays (12 kV) or soft x-rays (20 to 50 kV) delivered at a depth of approximately 1 mm have been used for the treatment of LM and LMM. Due to the low tissue penetration depth, Grenz rays can be safely given with total doses of at least 100 Gy. In one study, low energy (12 kV) Grenz rays (total dose 100 to 120 Gy in 10 to 12 fractions given at three- to four-day intervals) delivered at a depth of approximately 1 mm were used in 93 patients with LM with a recurrence rate of 5.4 percent after a mean time of 46 months [<a href="#rid5">5</a>].</p><p>Data on the use of RT in LM are mainly derived from retrospective series using various definitions of local control with variable follow-up periods [<a href="#rid95">95,96</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In an Australian review of eight retrospective, single-institution studies including 349 patients with LM treated primarily with RT, the overall recurrence rate was 5 percent after a median follow-up of three years [<a href="#rid94">94</a>]. Progression to LMM occurred in 1.4 percent of patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another series of 593 patients with LMs and early LMM treated with Grenz rays as primary therapy, partial surgical removal followed by RT alone, and wide excision followed by postoperative RT, the clearance rates were 83, 90, and 97 percent, respectively, after a median follow-up time of approximately five years [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A systemic review of 14 retrospective studies published between 1970 and 2019 showed recurrence rates of 0 to 31 percent [<a href="#rid97">97</a>]. A total of 1243 lesions (1075 LMs and 168 LMMs) were treated with a range of RT fractionations (42 to 160 Gy in 3 to 13 fractions) using a variety of techniques, including Grenz rays, superficial therapy, and orthovoltage therapy.</p><p></p><p>In general, these studies reported good to excellent cosmetic results for most patients, but late skin changes were reported in up to 20 percent.</p><p class="headingAnchor" id="H244299079"><span class="h3">Topical imiquimod</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">Imiquimod</a> 5% cream is approved by the US Food and Drug Administration for the treatment of actinic keratoses, superficial basal cell carcinomas, and warts. It has been used off label as primary treatment for LM in patients in whom surgery is not feasible or as adjuvant therapy after narrow-margin surgical resection or incomplete histologic resection [<a href="#rid98">98</a>]. The mechanism of action proposed is that imiquimod induces a local inflammatory response of T helper lymphocytes mixed with cytotoxic cells, monocytes, and macrophages, leading to a cytotoxic T cell-mediated immune response against the tumor [<a href="#rid99">99</a>].</p><p>Several systematic reviews of retrospective case series and a few randomized and nonrandomized studies support the use of <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a> in patients with LM who are poor surgical candidates based on reported clinical and histopathologic response rates of over 70 percent [<a href="#rid96">96,98,100,101</a>]. However, the optimal frequency of application and duration of treatment with imiquimod have not been determined [<a href="#rid102">102</a>].</p><p>A 2017 systematic review of 40 observational studies and one randomized trial including 509 patients with LM treated with topical <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a> one to seven times per week for 4 to 36 weeks found a complete clinical clearance rate of 78.3 percent [<a href="#rid101">101</a>]. Post-treatment histopathologic examination performed in 370 patients demonstrated histopathologic clearance in 77 percent. The recurrence rate was 2.2 percent after a mean follow-up period of 18.6 months. In nine patients (1.8 percent), LM progressed to LMM an average of 3.9 months (range 0 to 11 months) after completion of treatment.</p><p>However, a subsequent small, single-arm trial found a much lower pathologic clearance rate [<a href="#rid103">103</a>]. In this study, 28 patients older than 45 years with primary untreated and histologically confirmed LM were treated with <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a> five times per week for 12 weeks and then underwent complete surgical excision of the lesion. Following imiquimod treatment, only 10 patients (37 percent, 95% CI 19-58 percent) achieved the primary outcome (complete histologic clearance); partial regression and definite residual LM were observed in nine and seven patients, respectively [<a href="#rid103">103</a>].</p><p class="headingAnchor" id="H244299100"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Lentigo maligna (LM) has a tendency for subclinical spread. Atypical melanocytes often extend for a considerable distance from the clinical margin of LM, sometimes involving "skip" areas. This phenomenon is described as the "field effect" and is responsible for recurrence of LM at the edge after an initial, apparently successful treatment. However, in the absence of progression to lentigo maligna melanoma (LMM), LM does not shorten life expectancy. In a review of 270 patients with LM (n = 124) or LMM who underwent one or multiple surgeries until complete excision was achieved, there were no disease-related deaths among patients with LMM [<a href="#rid104">104</a>].</p><p>Recurrence may occur after a prolonged disease-free interval, making assessment of the efficacy of therapy difficult in studies with follow-up time ≤5 years. A few retrospective studies have reported recurrence rates for conventional wide surgical excision of 6 to 9 percent after a mean follow-up time of 5 to 10 years [<a href="#rid65">65-68</a>]. In a single institution review of 649 cases of LM and thin LMM treated surgically, a local recurrence was reported in 41 cases (6.3 percent) [<a href="#rid105">105</a>]. Among 29 cases with histologically documented recurrence, the median time to recurrence was 49 months (range 7 to 194).</p><p>Recurrence rates of 0 to 2 percent have been reported for LM excised by Mohs micrographic surgery (MMS) after a follow-up time of 29 to 38 months [<a href="#rid65">65,84,89-91</a>].</p><p class="headingAnchor" id="H244299107"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>There is no evidence base to determine the optimal follow-up for patients with lentigo maligna (LM). We typically see patients twice yearly lifelong, as recurrence of LM can occur after many years, and these patients have an increased risk of melanoma and nonmelanoma skin cancers.</p><p>We perform a full-body skin examination at each follow-up visit. Examination for recurrent lesions or new primary lesions is enhanced by the use of a Wood's light in a darkened room, dermoscopy, or, where available, reflectance confocal microscopy (RCM) [<a href="#rid106">106</a>].</p><p class="headingAnchor" id="H300581201"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118501.html" rel="external">"Society guideline links: Melanoma screening, prevention, diagnosis, and management"</a> and  <a class="medical medical_society_guidelines" href="/d/html/123058.html" rel="external">"Society guideline links: Mohs surgery"</a>.)</p><p class="headingAnchor" id="H652546"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and natural history</strong> – Lentigo maligna (LM) is a slowly evolving type of melanoma in situ that typically occurs in the sun-damaged skin of the face and neck of older individuals  (<a class="graphic graphic_picture graphicRef62052 graphicRef59591 graphicRef68787 graphicRef75238 graphicRef77206" href="/d/graphic/62052.html" rel="external">picture 1A-E</a>). The risk of progression to invasive lentigo maligna melanoma (LMM) ranges from 5 to 20 percent. The development of darker pigmentation, sharper borders, or elevated or nodular areas are clinical signs of progression. (See <a class="local">'Epidemiology and natural history'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Clinically, LM presents as an atypical macular lesion characterized by irregular shape, variegated color, and variable size  (<a class="graphic graphic_picture graphicRef62052 graphicRef59591 graphicRef68787 graphicRef75238 graphicRef77206" href="/d/graphic/62052.html" rel="external">picture 1A-E</a>). Dermoscopic features of LM include asymmetrical, pigmented follicular openings (atypical pseudonetwork); angulated lines/rhomboidal structures; and gray dots and globules  (<a class="graphic graphic_picture graphicRef68828" href="/d/graphic/68828.html" rel="external">picture 5A</a>). The surrounding skin typically shows evidence of chronic solar damage (solar elastosis, solar lentigines, or actinic keratoses). (See <a class="local">'Clinical features'</a> above and <a class="local">'Dermoscopic features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of LM is made by histologic examination. Excisional biopsy with narrow margins is ideal for diagnosis. For large lesions or lesions located in cosmetically sensitive areas, it is acceptable to perform one or more incisional biopsies of the most irregular or heavily pigmented areas. Dermoscopy may be helpful in the selection of the biopsy site. Histologically, LM is characterized by an increased number of atypical melanocytes, often spindle shaped, arranged in single cells or in small nests along the dermoepidermal junction. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Histopathologic features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Surgical excision</strong> – We suggest surgical excision, rather than radiation therapy (RT) or topical <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a>, as first-line treatment for LM (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Surgical margins of 0.5 to 1 cm are an accepted standard for wide local excision. If available, surgical techniques that allow complete margin control, such as staged excision with permanent sections ("slow Mohs"), are a preferred option for LMs located in facial areas, where sparing normal tissue is essential to preserve cosmetic appearance and function  (<a class="graphic graphic_figure graphicRef103749" href="/d/graphic/103749.html" rel="external">figure 1</a>). (See <a class="local">'Surgery'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonsurgical therapies</strong> – Nonsurgical therapies, such as RT and topical <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a>, are treatment options for older patients who are not surgical candidates and for patients in whom surgical excision is not feasible or reconstruction is anticipated as difficult. Main drawbacks of nonsurgical approaches are the lack of histologic examination of the entire tumor for foci of invasive melanoma not evident at the initial biopsy and lack of histologic margin control. RT or imiquimod may also be used as adjuvant treatment in patients with positive margins following surgical excision, when further surgical resection is not feasible. (See <a class="local">'Nonsurgical therapies'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">World Health Organization Classification of Tumors. Pathology &amp; Genetics. Skin Tumors. Chapter 2. Melanocytic Tumors. www.iarc.fr/en/publications/pdfs-online/pat-gen/bb6/bb6-chap2.pdf (Accessed on November 29, 2011).</li><li><a class="nounderline abstract_t">Hutchinson J. Notes on the cancerous process and on new growths in general. Arch Surg (London) 1890; 2:83.</a></li><li><a class="nounderline abstract_t">Dubreuilh MW. De la melanose circonscrite precancereuse. Ann Dermatol Syphil 1912; 3:129, 205.</a></li><li><a class="nounderline abstract_t">Cohen LM. Lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol 1995; 33:923.</a></li><li><a class="nounderline abstract_t">Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol 2002; 146:1042.</a></li><li><a class="nounderline abstract_t">Swetter SM, Boldrick JC, Jung SY, et al. Increasing incidence of lentigo maligna melanoma subtypes: northern California and national trends 1990-2000. J Invest Dermatol 2005; 125:685.</a></li><li><a class="nounderline abstract_t">Chen Q, Zheng M, Ling C. Incidence trends of lentigo maligna and lentigo maligna melanoma in the United States from 2000 to 2019. Int J Dermatol 2024.</a></li><li><a class="nounderline abstract_t">Kvaskoff M, Siskind V, Green AC. Risk factors for lentigo maligna melanoma compared with superficial spreading melanoma: a case-control study in Australia. Arch Dermatol 2012; 148:164.</a></li><li><a class="nounderline abstract_t">Gaudy-Marqueste C, Madjlessi N, Guillot B, et al. Risk factors in elderly people for lentigo maligna compared with other melanomas: a double case-control study. Arch Dermatol 2009; 145:418.</a></li><li><a class="nounderline abstract_t">Jackson R, Williamson GS, Beattie WG. Lentigo maligna and malignant melanoma. Can Med Assoc J 1966; 95:846.</a></li><li><a class="nounderline abstract_t">Grinspan D, Paz A, Abulafia J, Mosto S. [Melanoma (Hutchinson's lentigo maligna) having spontaneous regression. A case of immunologic importance]. Med Cutan Ibero Lat Am 1980; 8:33.</a></li><li><a class="nounderline abstract_t">Clark WH Jr, Mihm MC Jr. Lentigo maligna and lentigo-maligna melanoma. Am J Pathol 1969; 55:39.</a></li><li><a class="nounderline abstract_t">Weinstock MA, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol 1987; 116:303.</a></li><li><a class="nounderline abstract_t">Penneys NS. Microinvasive lentigo maligna melanoma. J Am Acad Dermatol 1987; 17:675.</a></li><li><a class="nounderline abstract_t">Bosbous MW, Dzwierzynski WW, Neuburg M. Staged excision of lentigo maligna and lentigo maligna melanoma: a 10-year experience. Plast Reconstr Surg 2009; 124:1947.</a></li><li><a class="nounderline abstract_t">Hazan C, Dusza SW, Delgado R, et al. Staged excision for lentigo maligna and lentigo maligna melanoma: A retrospective analysis of 117 cases. J Am Acad Dermatol 2008; 58:142.</a></li><li><a class="nounderline abstract_t">Somach SC, Taira JW, Pitha JV, Everett MA. Pigmented lesions in actinically damaged skin. Histopathologic comparison of biopsy and excisional specimens. Arch Dermatol 1996; 132:1297.</a></li><li><a class="nounderline abstract_t">Duarte AF, Sousa-Pinto B, Barros AM, et al. Lentigo Maligna - Not Always a Face and Neck Disease of the Elderly. Dermatology 2018; 234:37.</a></li><li><a class="nounderline abstract_t">Martínez-Leboráns L, Garcías-Ladaria J, Oliver-Martínez V, Alegre de Miquel V. Extrafacial Lentigo Maligna: A Report on 14 Cases and a Review of the Literature. Actas Dermosifiliogr 2016; 107:e57.</a></li><li><a class="nounderline abstract_t">Abdulla FR, Kerns MJ, Mutasim DF. Amelanotic lentigo maligna: a report of three cases and review of the literature. J Am Acad Dermatol 2010; 62:857.</a></li><li><a class="nounderline abstract_t">Chen LL, Jaimes N, Barker CA, et al. Desmoplastic melanoma: a review. J Am Acad Dermatol 2013; 68:825.</a></li><li><a class="nounderline abstract_t">Argenziano G, Soyer HP, Chimenti S, et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol 2003; 48:679.</a></li><li><a class="nounderline abstract_t">Stolz W, Schiffner R, Burgdorf WH. Dermatoscopy for facial pigmented skin lesions. Clin Dermatol 2002; 20:276.</a></li><li><a class="nounderline abstract_t">Akay BN, Kocyigit P, Heper AO, Erdem C. Dermatoscopy of flat pigmented facial lesions: diagnostic challenge between pigmented actinic keratosis and lentigo maligna. Br J Dermatol 2010; 163:1212.</a></li><li><a class="nounderline abstract_t">Zalaudek I, Ferrara G, Leinweber B, et al. Pitfalls in the clinical and dermoscopic diagnosis of pigmented actinic keratosis. J Am Acad Dermatol 2005; 53:1071.</a></li><li><a class="nounderline abstract_t">Schiffner R, Schiffner-Rohe J, Vogt T, et al. Improvement of early recognition of lentigo maligna using dermatoscopy. J Am Acad Dermatol 2000; 42:25.</a></li><li><a class="nounderline abstract_t">Tiodorovic-Zivkovic D, Argenziano G, Lallas A, et al. Age, gender, and topography influence the clinical and dermoscopic appearance of lentigo maligna. J Am Acad Dermatol 2015; 72:801.</a></li><li><a class="nounderline abstract_t">Connolly KL, Giordano C, Dusza S, et al. Follicular involvement is frequent in lentigo maligna: Implications for treatment. J Am Acad Dermatol 2019; 80:532.</a></li><li><a class="nounderline abstract_t">Weyers W, Bonczkowitz M, Weyers I, et al. Melanoma in situ versus melanocytic hyperplasia in sun-damaged skin. Assessment of the significance of histopathologic criteria for differential diagnosis. Am J Dermatopathol 1996; 18:560.</a></li><li><a class="nounderline abstract_t">Trotter MJ. Melanoma margin assessment. Clin Lab Med 2011; 31:289.</a></li><li><a class="nounderline abstract_t">El Shabrawi-Caelen L, Kerl H, Cerroni L. Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis. Am J Dermatopathol 2004; 26:364.</a></li><li><a class="nounderline abstract_t">Buonaccorsi JN, Prieto VG, Torres-Cabala C, et al. Diagnostic utility and comparative immunohistochemical analysis of MITF-1 and SOX10 to distinguish melanoma in situ and actinic keratosis: a clinicopathological and immunohistochemical study of 70 cases. Am J Dermatopathol 2014; 36:124.</a></li><li><a class="nounderline abstract_t">Kasprzak JM, Xu YG. Diagnosis and management of lentigo maligna: a review. Drugs Context 2015; 4:212281.</a></li><li><a class="nounderline abstract_t">Langley RG, Burton E, Walsh N, et al. In vivo confocal scanning laser microscopy of benign lentigines: comparison to conventional histology and in vivo characteristics of lentigo maligna. J Am Acad Dermatol 2006; 55:88.</a></li><li><a class="nounderline abstract_t">Ahlgrimm-Siess V, Massone C, Scope A, et al. Reflectance confocal microscopy of facial lentigo maligna and lentigo maligna melanoma: a preliminary study. Br J Dermatol 2009; 161:1307.</a></li><li><a class="nounderline abstract_t">Wurm EM, Curchin CE, Lambie D, et al. Confocal features of equivocal facial lesions on severely sun-damaged skin: four case studies with dermatoscopic, confocal, and histopathologic correlation. J Am Acad Dermatol 2012; 66:463.</a></li><li><a class="nounderline abstract_t">Laimer M, Arzberger E, Kirchner CA, et al. Noninvasive RCM for Differentiation of Melanotic Macules From Melanocytic Lesions-Blinded Evaluation of a Series of 42 Pigmented Macules. Dermatol Surg 2017; 43:911.</a></li><li><a class="nounderline abstract_t">Cinotti E, Labeille B, Debarbieux S, et al. Dermoscopy vs. reflectance confocal microscopy for the diagnosis of lentigo maligna. J Eur Acad Dermatol Venereol 2018; 32:1284.</a></li><li><a class="nounderline abstract_t">Pellacani G, De Carvalho N, Ciardo S, et al. The smart approach: feasibility of lentigo maligna superficial margin assessment with hand-held reflectance confocal microscopy technology. J Eur Acad Dermatol Venereol 2018; 32:1687.</a></li><li><a class="nounderline abstract_t">Yélamos O, Cordova M, Blank N, et al. Correlation of Handheld Reflectance Confocal Microscopy With Radial Video Mosaicing for Margin Mapping of Lentigo Maligna and Lentigo Maligna Melanoma. JAMA Dermatol 2017; 153:1278.</a></li><li><a class="nounderline abstract_t">Guitera P, Pellacani G, Crotty KA, et al. The impact of in vivo reflectance confocal microscopy on the diagnostic accuracy of lentigo maligna and equivocal pigmented and nonpigmented macules of the face. J Invest Dermatol 2010; 130:2080.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Cutaneous melanoma. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf (Accessed on August 23, 2021).</li><li><a class="nounderline abstract_t">Mataca E, Migaldi M, Cesinaro AM. Impact of Dermoscopy and Reflectance Confocal Microscopy on the Histopathologic Diagnosis of Lentigo Maligna/Lentigo Maligna Melanoma. Am J Dermatopathol 2018; 40:884.</a></li><li><a class="nounderline abstract_t">Tio D, Prinsen CAC, Dréno B, et al. Variation in the diagnosis and clinical management of lentigo maligna across Europe: a survey study among European Association of Dermatologists and Venereologists members. J Eur Acad Dermatol Venereol 2018; 32:1476.</a></li><li><a class="nounderline abstract_t">Liu A, Botkin A, Murray C, et al. Treatment for Lentigo Maligna of the Head and Neck: Survey of Practices in Ontario, Canada. Dermatol Surg 2018; 44:918.</a></li><li><a class="nounderline abstract_t">Tzellos T, Kyrgidis A, Mocellin S, et al. Interventions for melanoma in situ, including lentigo maligna. Cochrane Database Syst Rev 2014; :CD010308.</a></li><li><a class="nounderline abstract_t">Marsden JR, Newton-Bishop JA, Burrows L, et al. Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol 2010; 163:238.</a></li><li><a class="nounderline abstract_t">Bichakjian CK, Halpern AC, Johnson TM, et al. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol 2011; 65:1032.</a></li><li class="breakAll">Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand. Cancer Council Australia and Australian Cancer Network, Sydney and New Zealand Guidelines Group, Wellington (2008). www.health.govt.nz/system/files/documents/publications/melanoma-guideline-nov08-v2.pdf (Accessed on November 29, 2011).</li><li><a class="nounderline abstract_t">Sladden MJ, Nieweg OE, Howle J, et al. Updated evidence-based clinical practice guidelines for the diagnosis and management of melanoma: definitive excision margins for primary cutaneous melanoma. Med J Aust 2018; 208:137.</a></li><li><a class="nounderline abstract_t">Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. Eur J Cancer 2016; 63:201.</a></li><li><a class="nounderline abstract_t">Robinson M, Primiero C, Guitera P, et al. Evidence-Based Clinical Practice Guidelines for the Management of Patients with Lentigo Maligna. Dermatology 2020; 236:111.</a></li><li class="breakAll">Cancer Council Australia Melanoma Guidelines Working Party. Clinical practice guidelines for the diagnosis and management of melanoma. Sydney: Cancer Council Australia. https://wiki.cancer.org.au/australia/Guidelines:Melanoma (Accessed on November 07, 2019).</li><li class="breakAll">National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, Version 3.2023. Melanoma: Cutaneous. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf (Accessed on January 08, 2024).</li><li><a class="nounderline abstract_t">Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 2019; 80:208.</a></li><li><a class="nounderline abstract_t">Bouzari N, Olbricht S. Histologic pitfalls in the Mohs technique. Dermatol Clin 2011; 29:261.</a></li><li><a class="nounderline abstract_t">Hibler BP, Cordova M, Wong RJ, Rossi AM. Intraoperative real-time reflectance confocal microscopy for guiding surgical margins of lentigo maligna melanoma. Dermatol Surg 2015; 41:980.</a></li><li><a class="nounderline abstract_t">Couty E, Tognetti L, Labeille B, et al. In vivo reflectance confocal microscopy combined with the 'spaghetti technique' for the identification of surgical margins of lentigo maligna: experience in 70 patients. J Eur Acad Dermatol Venereol 2018; 32:e366.</a></li><li><a class="nounderline abstract_t">Huilgol SC, Selva D, Chen C, et al. Surgical margins for lentigo maligna and lentigo maligna melanoma: the technique of mapped serial excision. Arch Dermatol 2004; 140:1087.</a></li><li><a class="nounderline abstract_t">Albertini JG, Elston DM, Libow LF, et al. Mohs micrographic surgery for melanoma: a case series, a comparative study of immunostains, an informative case report, and a unique mapping technique. Dermatol Surg 2002; 28:656.</a></li><li><a class="nounderline abstract_t">Zalla MJ, Lim KK, Dicaudo DJ, Gagnot MM. Mohs micrographic excision of melanoma using immunostains. Dermatol Surg 2000; 26:771.</a></li><li><a class="nounderline abstract_t">Bricca GM, Brodland DG, Ren D, Zitelli JA. Cutaneous head and neck melanoma treated with Mohs micrographic surgery. J Am Acad Dermatol 2005; 52:92.</a></li><li><a class="nounderline abstract_t">Kunishige JH, Brodland DG, Zitelli JA. Surgical margins for melanoma in situ. J Am Acad Dermatol 2012; 66:438.</a></li><li><a class="nounderline abstract_t">Kunishige JH, Doan L, Brodland DG, Zitelli JA. Comparison of surgical margins for lentigo maligna versus melanoma in situ. J Am Acad Dermatol 2019; 81:204.</a></li><li><a class="nounderline abstract_t">Hou JL, Reed KB, Knudson RM, et al. Five-year outcomes of wide excision and Mohs micrographic surgery for primary lentigo maligna in an academic practice cohort. Dermatol Surg 2015; 41:211.</a></li><li><a class="nounderline abstract_t">Tsang RW, Liu FF, Wells W, Payne DG. Lentigo maligna of the head and neck. Results of treatment by radiotherapy. Arch Dermatol 1994; 130:1008.</a></li><li><a class="nounderline abstract_t">Coleman WP 3rd, Davis RS, Reed RJ, Krementz ET. Treatment of lentigo maligna and lentigo maligna melanoma. J Dermatol Surg Oncol 1980; 6:476.</a></li><li><a class="nounderline abstract_t">Wilson JB, Walling HW, Scupham RK, et al. Staged Excision for Lentigo Maligna and Lentigo Maligna Melanoma: Analysis of Surgical Margins and Long-term Recurrence in 68 Cases from a Single Practice. J Clin Aesthet Dermatol 2016; 9:25.</a></li><li><a class="nounderline abstract_t">Bub JL, Berg D, Slee A, Odland PB. Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5-year follow-up. Arch Dermatol 2004; 140:552.</a></li><li><a class="nounderline abstract_t">Agarwal-Antal N, Bowen GM, Gerwels JW. Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines. J Am Acad Dermatol 2002; 47:743.</a></li><li><a class="nounderline abstract_t">Hill DC, Gramp AA. Surgical treatment of lentigo maligna and lentigo maligna melanoma. Australas J Dermatol 1999; 40:25.</a></li><li><a class="nounderline abstract_t">Malhotra R, Chen C, Huilgol SC, et al. Mapped serial excision for periocular lentigo maligna and lentigo maligna melanoma. Ophthalmology 2003; 110:2011.</a></li><li><a class="nounderline abstract_t">McGuire LK, Disa JJ, Lee EH, et al. Melanoma of the lentigo maligna subtype: diagnostic challenges and current treatment paradigms. Plast Reconstr Surg 2012; 129:288e.</a></li><li><a class="nounderline abstract_t">David AP, Miller MQ, Park SS, Christophel JJ. Comparison of Outcomes of Early vs Delayed Graft Reconstruction of Mohs Micrographic Surgery Defects. JAMA Facial Plast Surg 2019; 21:89.</a></li><li><a class="nounderline abstract_t">Johnson TM, Headington JT, Baker SR, Lowe L. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the "square" procedure. J Am Acad Dermatol 1997; 37:758.</a></li><li><a class="nounderline abstract_t">Anderson KW, Baker SR, Lowe L, et al. Treatment of head and neck melanoma, lentigo maligna subtype: a practical surgical technique. Arch Facial Plast Surg 2001; 3:202.</a></li><li><a class="nounderline abstract_t">Gaudy-Marqueste C, Perchenet AS, Taséi AM, et al. The "spaghetti technique": an alternative to Mohs surgery or staged surgery for problematic lentiginous melanoma (lentigo maligna and acral lentiginous melanoma). J Am Acad Dermatol 2011; 64:113.</a></li><li><a class="nounderline abstract_t">Möller MG, Pappas-Politis E, Zager JS, et al. Surgical management of melanoma-in-situ using a staged marginal and central excision technique. Ann Surg Oncol 2009; 16:1526.</a></li><li><a class="nounderline abstract_t">Mahoney MH, Joseph M, Temple CL. The perimeter technique for lentigo maligna: an alternative to Mohs micrographic surgery. J Surg Oncol 2005; 91:120.</a></li><li><a class="nounderline abstract_t">Garcia D, Eilers RE, Jiang SB. Recurrence Rate of Melanoma in Situ when Treated with Serial Disk Staged Excision: A Case Series. J Clin Investig Dermatol 2017; 5.</a></li><li><a class="nounderline abstract_t">Demirci H, Johnson TM, Frueh BR, et al. Management of periocular cutaneous melanoma with a staged excision technique and permanent sections the square procedure. Ophthalmology 2008; 115:2295.</a></li><li><a class="nounderline abstract_t">de Vries K, Greveling K, Prens LM, et al. Recurrence rate of lentigo maligna after micrographically controlled staged surgical excision. Br J Dermatol 2016; 174:588.</a></li><li><a class="nounderline abstract_t">Kwon SY, Miller SJ. Mohs surgery for melanoma in situ. Dermatol Clin 2011; 29:175.</a></li><li><a class="nounderline abstract_t">Bhardwaj SS, Tope WD, Lee PK. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma using Mel-5 immunostaining: University of Minnesota experience. Dermatol Surg 2006; 32:690.</a></li><li><a class="nounderline abstract_t">Cherpelis BS, Moore R, Ladd S, et al. Comparison of MART-1 frozen sections to permanent sections using a rapid 19-minute protocol. Dermatol Surg 2009; 35:207.</a></li><li><a class="nounderline abstract_t">Bricca GM, Brodland DG, Zitelli JA. Immunostaining melanoma frozen sections: the 1-hour protocol. Dermatol Surg 2004; 30:403.</a></li><li><a class="nounderline abstract_t">Bene NI, Healy C, Coldiron BM. Mohs micrographic surgery is accurate 95.1% of the time for melanoma in situ: a prospective study of 167 cases. Dermatol Surg 2008; 34:660.</a></li><li><a class="nounderline abstract_t">Iorizzo LJ 3rd, Chocron I, Lumbang W, Stasko T. Importance of vertical pathology of debulking specimens during Mohs micrographic surgery for lentigo maligna and melanoma in situ. Dermatol Surg 2013; 39:365.</a></li><li><a class="nounderline abstract_t">Temple CL, Arlette JP. Mohs micrographic surgery in the treatment of lentigo maligna and melanoma. J Surg Oncol 2006; 94:287.</a></li><li><a class="nounderline abstract_t">Bienert TN, Trotter MJ, Arlette JP. Treatment of cutaneous melanoma of the face by Mohs micrographic surgery. J Cutan Med Surg 2003; 7:25.</a></li><li><a class="nounderline abstract_t">Dawn ME, Dawn AG, Miller SJ. Mohs surgery for the treatment of melanoma in situ: a review. Dermatol Surg 2007; 33:395.</a></li><li><a class="nounderline abstract_t">Demer AM, Vance KK, Cheraghi N, et al. Benefit of Mohs Micrographic Surgery Over Wide Local Excision for Melanoma of the Head and Neck: A Rational Approach to Treatment. Dermatol Surg 2019; 45:381.</a></li><li><a class="nounderline abstract_t">Zalaudek I, Horn M, Richtig E, et al. Local recurrence in melanoma in situ: influence of sex, age, site of involvement and therapeutic modalities. Br J Dermatol 2003; 148:703.</a></li><li><a class="nounderline abstract_t">Fogarty GB, Hong A, Scolyer RA, et al. Radiotherapy for lentigo maligna: a literature review and recommendations for treatment. Br J Dermatol 2014; 170:52.</a></li><li><a class="nounderline abstract_t">Hedblad MA, Mallbris L. Grenz ray treatment of lentigo maligna and early lentigo maligna melanoma. J Am Acad Dermatol 2012; 67:60.</a></li><li><a class="nounderline abstract_t">Read T, Noonan C, David M, et al. A systematic review of non-surgical treatments for lentigo maligna. J Eur Acad Dermatol Venereol 2016; 30:748.</a></li><li><a class="nounderline abstract_t">Hendrickx A, Cozzio A, Plasswilm L, Panje CM. Radiotherapy for lentigo maligna and lentigo maligna melanoma - a systematic review. Radiat Oncol 2020; 15:174.</a></li><li><a class="nounderline abstract_t">Swetter SM, Chen FW, Kim DD, Egbert BM. Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type. J Am Acad Dermatol 2015; 72:1047.</a></li><li><a class="nounderline abstract_t">Wolf IH, Cerroni L, Kodama K, Kerl H. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol 2005; 141:510.</a></li><li><a class="nounderline abstract_t">Mora AN, Karia PS, Nguyen BM. A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance. J Am Acad Dermatol 2015; 73:205.</a></li><li><a class="nounderline abstract_t">Tio D, van der Woude J, Prinsen CAC, et al. A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures. J Eur Acad Dermatol Venereol 2017; 31:616.</a></li><li><a class="nounderline abstract_t">Swetter SM. Challenges of treating melanoma in situ, lentigo maligna type: is pathological clearance the gold standard? Br J Dermatol 2017; 176:1115.</a></li><li><a class="nounderline abstract_t">Marsden JR, Fox R, Boota NM, et al. Effect of topical imiquimod as primary treatment for lentigo maligna: the LIMIT-1 study. Br J Dermatol 2017; 176:1148.</a></li><li><a class="nounderline abstract_t">Gambichler T, Kempka J, Kampilafkos P, et al. Clinicopathological characteristics of 270 patients with lentigo maligna and lentigo maligna melanoma: data from a German skin cancer centre. Br J Dermatol 2014; 171:1605.</a></li><li><a class="nounderline abstract_t">Connolly KL, Hibler BP, Lee EH, et al. Locally Recurrent Lentigo Maligna and Lentigo Maligna Melanoma: Characteristics and Time to Recurrence After Surgery. Dermatol Surg 2017; 43:792.</a></li><li><a class="nounderline abstract_t">Erfan N, Kang HY, Cardot-Leccia N, et al. Reflectance confocal microscopy for recurrent lentigo maligna. Dermatol Surg 2011; 37:1519.</a></li></ol></div><div id="topicVersionRevision">Topic 13520 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="www.iarc.fr/en/publications/pdfs-online/pat-gen/bb6/bb6-chap2.pdf" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : World Health Organization Classification of Tumors. Pathology &amp; Genetics. Skin Tumors. Chapter 2. Melanocytic Tumors. www.iarc.fr/en/publications/pdfs-online/pat-gen/bb6/bb6-chap2.pdf (Accessed on November 29, 2011).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Notes on the cancerous process and on new growths in general</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : De la melanose circonscrite precancereuse</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7490362" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Lentigo maligna and lentigo maligna melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12072074" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16185266" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Increasing incidence of lentigo maligna melanoma subtypes: northern California and national trends 1990-2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38173361" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Incidence trends of lentigo maligna and lentigo maligna melanoma in the United States from 2000 to 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22004881" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risk factors for lentigo maligna melanoma compared with superficial spreading melanoma: a case-control study in Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19380663" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Risk factors in elderly people for lentigo maligna compared with other melanomas: a double case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5922502" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Lentigo maligna and malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7022050" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : [Melanoma (Hutchinson's lentigo maligna) having spontaneous regression. A case of immunologic importance].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5776171" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Lentigo maligna and lentigo-maligna melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3567069" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The risk of progression of lentigo maligna to lentigo maligna melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3312317" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Microinvasive lentigo maligna melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19952650" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Staged excision of lentigo maligna and lentigo maligna melanoma: a 10-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18029055" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Staged excision for lentigo maligna and lentigo maligna melanoma: A retrospective analysis of 117 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8915306" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pigmented lesions in actinically damaged skin. Histopathologic comparison of biopsy and excisional specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29895005" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Lentigo Maligna - Not Always a Face and Neck Disease of the Elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27180003" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Extrafacial Lentigo Maligna: A Report on 14 Cases and a Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19766347" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Amelanotic lentigo maligna: a report of three cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23267722" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Desmoplastic melanoma: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12734496" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12074867" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Dermatoscopy for facial pigmented skin lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21083845" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Dermatoscopy of flat pigmented facial lesions: diagnostic challenge between pigmented actinic keratosis and lentigo maligna.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16310072" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pitfalls in the clinical and dermoscopic diagnosis of pigmented actinic keratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10607316" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Improvement of early recognition of lentigo maligna using dermatoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25774013" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Age, gender, and topography influence the clinical and dermoscopic appearance of lentigo maligna.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30266559" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Follicular involvement is frequent in lentigo maligna: Implications for treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8989926" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Melanoma in situ versus melanocytic hyperplasia in sun-damaged skin. Assessment of the significance of histopathologic criteria for differential diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21549242" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Melanoma margin assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15365366" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23782678" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Diagnostic utility and comparative immunohistochemical analysis of MITF-1 and SOX10 to distinguish melanoma in situ and actinic keratosis: a clinicopathological and immunohistochemical study of 70 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26082796" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Diagnosis and management of lentigo maligna: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16781299" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : In vivo confocal scanning laser microscopy of benign lentigines: comparison to conventional histology and in vivo characteristics of lentigo maligna.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19566662" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Reflectance confocal microscopy of facial lentigo maligna and lentigo maligna melanoma: a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21978574" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Confocal features of equivocal facial lesions on severely sun-damaged skin: four case studies with dermatoscopic, confocal, and histopathologic correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28430732" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Noninvasive RCM for Differentiation of Melanotic Macules From Melanocytic Lesions-Blinded Evaluation of a Series of 42 Pigmented Macules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29341263" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Dermoscopy vs. reflectance confocal microscopy for the diagnosis of lentigo maligna.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29704275" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The smart approach: feasibility of lentigo maligna superficial margin assessment with hand-held reflectance confocal microscopy technology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29049429" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Correlation of Handheld Reflectance Confocal Microscopy With Radial Video Mosaicing for Margin Mapping of Lentigo Maligna and Lentigo Maligna Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20393481" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The impact of in vivo reflectance confocal microscopy on the diagnostic accuracy of lentigo maligna and equivocal pigmented and nonpigmented macules of the face.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20393481" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The impact of in vivo reflectance confocal microscopy on the diagnostic accuracy of lentigo maligna and equivocal pigmented and nonpigmented macules of the face.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29933314" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Impact of Dermoscopy and Reflectance Confocal Microscopy on the Histopathologic Diagnosis of Lentigo Maligna/Lentigo Maligna Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29419913" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Variation in the diagnosis and clinical management of lentigo maligna across Europe: a survey study among European Association of Dermatologists and Venereologists members.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29543619" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Treatment for Lentigo Maligna of the Head and Neck: Survey of Practices in Ontario, Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25526608" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Interventions for melanoma in situ, including lentigo maligna.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20608932" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Revised U.K. guidelines for the management of cutaneous melanoma 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21868127" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21868127" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29438650" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Updated evidence-based clinical practice guidelines for the diagnosis and management of melanoma: definitive excision margins for primary cutaneous melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27367293" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31639788" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Evidence-Based Clinical Practice Guidelines for the Management of Patients with Lentigo Maligna.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31639788" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Evidence-Based Clinical Practice Guidelines for the Management of Patients with Lentigo Maligna.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31639788" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Evidence-Based Clinical Practice Guidelines for the Management of Patients with Lentigo Maligna.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30392755" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Guidelines of care for the management of primary cutaneous melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21421150" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Histologic pitfalls in the Mohs technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26050216" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Intraoperative real-time reflectance confocal microscopy for guiding surgical margins of lentigo maligna melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29573292" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : In vivo reflectance confocal microscopy combined with the 'spaghetti technique' for the identification of surgical margins of lentigo maligna: experience in 70 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15381549" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Surgical margins for lentigo maligna and lentigo maligna melanoma: the technique of mapped serial excision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12174054" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Mohs micrographic surgery for melanoma: a case series, a comparative study of immunostains, an informative case report, and a unique mapping technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10940065" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Mohs micrographic excision of melanoma using immunostains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15627086" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cutaneous head and neck melanoma treated with Mohs micrographic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22196979" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Surgical margins for melanoma in situ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31014825" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Comparison of surgical margins for lentigo maligna versus melanoma in situ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25590473" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Five-year outcomes of wide excision and Mohs micrographic surgery for primary lentigo maligna in an academic practice cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8053696" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Lentigo maligna of the head and neck. Results of treatment by radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7391322" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Treatment of lentigo maligna and lentigo maligna melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27386048" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Staged Excision for Lentigo Maligna and Lentigo Maligna Melanoma: Analysis of Surgical Margins and Long-term Recurrence in 68 Cases from a Single Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15148099" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12399768" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10098285" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Surgical treatment of lentigo maligna and lentigo maligna melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14522781" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Mapped serial excision for periocular lentigo maligna and lentigo maligna melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22286443" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Melanoma of the lentigo maligna subtype: diagnostic challenges and current treatment paradigms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30422211" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Comparison of Outcomes of Early vs Delayed Graft Reconstruction of Mohs Micrographic Surgery Defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9366823" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the "square" procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11497507" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Treatment of head and neck melanoma, lentigo maligna subtype: a practical surgical technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21167406" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The "spaghetti technique": an alternative to Mohs surgery or staged surgery for problematic lentiginous melanoma (lentigo maligna and acral lentiginous melanoma).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19050971" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Surgical management of melanoma-in-situ using a staged marginal and central excision technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16028282" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The perimeter technique for lentigo maligna: an alternative to Mohs micrographic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28936478" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Recurrence Rate of Melanoma in Situ when Treated with Serial Disk Staged Excision: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18692248" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Management of periocular cutaneous melanoma with a staged excision technique and permanent sections the square procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26616840" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Recurrence rate of lentigo maligna after micrographically controlled staged surgical excision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21421143" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Mohs surgery for melanoma in situ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16706765" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma using Mel-5 immunostaining: University of Minnesota experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19215257" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Comparison of MART-1 frozen sections to permanent sections using a rapid 19-minute protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15008870" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Immunostaining melanoma frozen sections: the 1-hour protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18261099" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Mohs micrographic surgery is accurate 95.1% of the time for melanoma in situ: a prospective study of 167 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23356872" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Importance of vertical pathology of debulking specimens during Mohs micrographic surgery for lentigo maligna and melanoma in situ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16917877" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Mohs micrographic surgery in the treatment of lentigo maligna and melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12447624" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Treatment of cutaneous melanoma of the face by Mohs micrographic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17430372" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Mohs surgery for the treatment of melanoma in situ: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30550523" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Benefit of Mohs Micrographic Surgery Over Wide Local Excision for Melanoma of the Head and Neck: A Rational Approach to Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12752127" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Local recurrence in melanoma in situ: influence of sex, age, site of involvement and therapeutic modalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24032599" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Radiotherapy for lentigo maligna: a literature review and recommendations for treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22030019" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Grenz ray treatment of lentigo maligna and early lentigo maligna melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26299846" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : A systematic review of non-surgical treatments for lentigo maligna.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32664998" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Radiotherapy for lentigo maligna and lentigo maligna melanoma - a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25791801" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15837872" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26088690" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27987308" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28504388" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Challenges of treating melanoma in situ, lentigo maligna type: is pathological clearance the gold standard?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27714781" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Effect of topical imiquimod as primary treatment for lentigo maligna: the LIMIT-1 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24958545" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Clinicopathological characteristics of 270 patients with lentigo maligna and lentigo maligna melanoma: data from a German skin cancer centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28296789" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Locally Recurrent Lentigo Maligna and Lentigo Maligna Melanoma: Characteristics and Time to Recurrence After Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21790847" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Reflectance confocal microscopy for recurrent lentigo maligna.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
